Literature DB >> 2945788

Presence of a macrophage-mediated suppressor cell mechanism during cell-mediated immune response in experimental visceral leishmaniasis.

H W Murray, S M Carriero, D M Donelly.   

Abstract

In susceptible BALB/c mice, systemic intracellular infection with Leishmania donovani provokes generation of adherent spleen cells which can suppress both mitogen- and specific-antigen-stimulated T-cell responses. To characterize the responsible suppressor cell, we irradiated (2,000 R) adherent spleen cells from L. donovani-infected mice or treated them with anti-Thy-1.2 antibody plus complement. Neither anti-T-cell treatment diminished the capacity to inhibit lymphocyte proliferative activity. In addition, as judged by morphologic and functional criteria, 80 to 90% of the adherent cells appeared to be macrophages. Four observations suggested an immunopathogenic role for these suppressor macrophages. (i) Their appearance and disappearance paralleled the establishment and resolution of L. donovani visceral infection in vivo. (ii) Suppressive effects included inhibition of production of the macrophage-activating lymphokine gamma interferon (IFN-gamma). (iii) On transfer into immune mice, suppressor macrophages impaired naturally acquired resistance to L. donovani. (iv) Inhibition of macrophage prostaglandin metabolism by indomethacin reduced suppressor activity in vitro and resulted in a 50% decrease in parasite visceral replication in vivo. In addition, prophylactic cyclophosphamide treatment inhibited the development of suppressor macrophages, and under these conditions visceral infection was rapidly controlled. These results suggested that disseminated L. donovani infection provokes a macrophage-mediated suppressor mechanism which appears to contribute to establishment of visceral leishmaniasis in a susceptible host.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945788      PMCID: PMC260187          DOI: 10.1128/iai.54.2.487-493.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Alterations of the immune response associated with chronic experimental leishmaniasis.

Authors:  B Arredondo; H Pérez
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

2.  The origin and significance of the distribution of parasites in visceral leishmaniasis.

Authors:  L A Stauber
Journal:  Trans N Y Acad Sci       Date:  1966-03

3.  Defective IFN-gamma production in the human neonate. II. Role of increased sensitivity to the suppressive effects of prostaglandin E.

Authors:  N Wakasugi; J L Virelizier; F Arenzana-Seisdedos; B Rothhut; J M Huerta; F Russo-Marie; W Fiers
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

4.  Arachidonic acid metabolism in murine leishmaniasis (Donovani): ex-vivo evidence for increased cyclooxygenase and 5-lipoxygenase activity in spleen cells.

Authors:  N E Reiner; C J Malemud
Journal:  Cell Immunol       Date:  1984-10-15       Impact factor: 4.868

5.  Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: immunosuppression by adherent spleen cells.

Authors:  A D Nickol; P F Bonventre
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

6.  Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: T-lymphocyte-mediated immunosuppression.

Authors:  A D Nickol; P F Bonventre
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

7.  Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice.

Authors:  D J Bradley; J Kirkley
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

8.  Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.

Authors:  H W Murray; G L Spitalny; C F Nathan
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

9.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

10.  Inhibition of plasmacytoma development in BALB/c mice by indomethacin.

Authors:  M Potter; J S Wax; A O Anderson; R P Nordan
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection.

Authors:  G M Anstead; B Chandrasekar; W Zhao; J Yang; L E Perez; P C Melby
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Characterization of protective T cells in the acquired response to Leishmania donovani in genetically determined cure (H-2b) and noncure (H-2d) mouse strains.

Authors:  O M Ulczak; E Ghadirian; E Skamene; J M Blackwell; P A Kongshavn
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

4.  Genome-Wide Analysis of c-MYC-Regulated mRNAs and miRNAs and c-MYC DNA-Binding by Next-Generation Sequencing.

Authors:  Rene Jackstadt; Markus Kaller; Antje Menssen; Heiko Hermeking
Journal:  Methods Mol Biol       Date:  2021

5.  Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation.

Authors:  A Cordeiro-Da-Silva; M C Borges; E Guilvard; A Ouaissi
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.

Authors:  H W Murray; M J Oca; A M Granger; R D Schreiber
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

7.  Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice.

Authors:  K E Squires; M Kirsch; S C Silverstein; A Acosta; M J McElrath; H W Murray
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

8.  Antigen-stimulated human interferon-gamma generation: role of accessory cells and their expressed or secreted products.

Authors:  C D Kelly; C M Russo; B Y Rubin; H W Murray
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

9.  The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.

Authors:  K C Carter; A J Baillie; A B Mullen
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

10.  Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters.

Authors:  C Gifawesen; J P Farrell
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.